Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized,Double-Blind,Placebo-Controlled,Ascending,Single-Dose Study of the Safety,Tolerability and Bioeffect of Intravenously Administered REGN727 in Healthy Volunteers
Brief Summary: This study will test the safety and tolerability (how the body reacts to the drug) of REGN727 compared with placebo (an inactive substance that contains no medicine) in healthy subjects. The study drug and placebo will be administered by intravenous (I.V) infusion at one clinic visit. There will be 14 clinic visits, which will include 4 overnight stays. Subjects will be monitored by the study staff for side effects and the body's response to the study drug. Vital signs(blood pressure, temperature, breathing and heart rate) will be checked, and blood and urine samples will be collected at some or all visits.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: cohort 3; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: cohort 4; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: cohort 5; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Intervention Type: DRUG; Name: REGN727; Assigned to Arm(s): Cohort 1, Cohort 2, cohort 3, cohort 4, cohort 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, cohort 3, cohort 4, cohort 5
B: Arm Label: Atorvastatin (statin rechallenge arm); Type: OTHER; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Drug: Placebo | Arm Label: Alirocumab 75 mg/ up to 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin (statin rechallenge arm) | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg, Atorvastatin (statin rechallenge arm), Ezetimibe
C: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab, Placebo Q2W
D: Arm Label: Part A: Atorvastatin 20 mg => Placebo; Type: OTHER; Interventions: Drug: Atorvastatin, Drug: Placebo to Atorvastatin | Arm Label: Part A: Placebo => Atorvastatin 20 mg; Type: OTHER; Interventions: Drug: Atorvastatin, Drug: Placebo to Atorvastatin | Arm Label: Part B: Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Other: Placebo to Evolocumab | Arm Label: Part B: Evolocumab; Type: EXPERIMENTAL; Interventions: Other: Placebo to Ezetimibe, Drug: Evolocumab | Arm Label: Part C: Open-label Evolocumab; Type: EXPERIMENTAL; Interventions: Drug: Evolocumab | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Part A: Atorvastatin 20 mg => Placebo, Part A: Placebo => Atorvastatin 20 mg | Intervention Type: DRUG; Name: Placebo to Atorvastatin; Assigned to Arm(s): Part A: Atorvastatin 20 mg => Placebo, Part A: Placebo => Atorvastatin 20 mg | Intervention Type: OTHER; Name: Placebo to Ezetimibe; Assigned to Arm(s): Part B: Evolocumab | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Part B: Ezetimibe | Intervention Type: OTHER; Name: Placebo to Evolocumab; Assigned to Arm(s): Part B: Ezetimibe | Intervention Type: DRUG; Name: Evolocumab; Assigned to Arm(s): Part B: Evolocumab, Part C: Open-label Evolocumab

Answer: A